Thrombolytic therapy in central retinal artery occlusion: Cutting edge therapy, standard of care therapy, or impractical therapy?

Current Opinion in Ophthalmology

Volumn 20, Issue 3, 2009, Pages 210-218

  Hazirr, Ribhi ^a   Dixon, James A ^b   Bhatti, M Tariq ^c,d  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

Central retinal artery occlusion; Emboli; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOGEN; CARBONATE DEHYDRATASE INHIBITOR; CEPHALOSPORIN; CLOPIDOGREL; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; METHYLPREDNISOLONE; PAPAVERINE; PENTOXIFYLLINE; PROSTAGLANDIN E1; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE; VALPROATE SEMISODIUM; VALPROIC ACID; VASODILATOR AGENT;

BLEEDING; BLEEDING TENDENCY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOGENIC SHOCK; CENTRAL RETINA ARTERY OCCLUSION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EXERCISE; FLUORESCENCE ANGIOGRAPHY; HEMATOMA; HEMODILUTION; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; INTRAOCULAR PRESSURE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MASSAGE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PARACENTESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; THERAPY EFFECT; TRANSIENT ISCHEMIC ATTACK; FIBRINOLYTIC THERAPY; RETINA ARTERY OCCLUSION;

FIBRINOLYTIC AGENTS; HUMANS; RETINAL ARTERY OCCLUSION; RISK FACTORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 65549107889     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328329b5d5     Document Type: Review

References (73)

1. Mangat HS. Retinal artery occlusion. Surv Ophthalmol 1995; 40:145- 156.
2. Chen CS, Lee AW. Management of acute central retinal artery occlusion. Nat Clin Pract Neurol 2008; 4:376-383.
3. Beatty S, Au Eong KG. Acute occlusion of the retinal arteries: current concepts and recent advances in diagnosis and management. J Accid Emerg Med 2000; 17:324-329.
4. Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol 1999; 128:733- 738.
5. Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol 2000; 11:462-467.
6. Schmidt D, Hetzel A, Geibel-Zehender A, et al. Systemic diseases in noninflammatory branch and central retinal artery occlusion: an overview of 416 patients. Eur J Med Res 2007; 12:595-603.
7. Wakefield MC, O'Donnell SD, Goff JM Jr. Re-evaluation of carotid duplex for visual complaints: who really needs to be studied? Ann Vase Surg 2003; 17:635-640.
8. Costello F, Gilberg S, Karsh J, et al. Bilateral simultaneous central retinal artery occlusions in Wegener granulomatosis. J Neuroophthalmol 2005; 25:29-32.
9. Hayreh SS, Zimmerman MB. Fundus changes in central retinal artery occlusion. Retina 2007; 27:276-289.
10. Shinoda K, Yamada K, Matsumoto CS, et al. Changes in retinal thickness are correlated with alterations of electroretinogram in eyes with central retinal artery occlusion. Graefes Arch Clin Exp Ophthalmol 2008; 246:949-954.
11. Suri MF, Nasar A, Hussein HM, et al. Intra-arterial thrombolysis for central retinal artery occlusion in United States: Nationwide In-patient Survey 2001 - 2003. J Neuroimaging 2007; 17:339-343.
12. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology 1989; 96:92-95.
13. Klein R, Klein BE, Jensen SC, et al. Retinal emboli and stroke: the Beaver Dam Eye Study. Arch Ophthalmol 1999; 117:1063-1068.
14. Wang JJ, Cugati S, Knudtson MD, etal. Retinal arteriolar emboli and long-term mortality: pooled data analysis from two older populations. Stroke 2006; 37:1833-1836.
15. Colucciello M. Retinal vascular disease in hypertension. Risk factor modification optimizes vision outcomes. Postgrad Med 2005; 117:33-38; 41 -42.
16. Lu N, Wang NL, Wang GL, et al. Vitreous surgery with direct central retinal artery massage for central retinal artery occlusion. Eye 2008. [Epub ahead of print]
17. Miller NR, Newman NJ, Biousse V, Kerrison JB, editors. Walsh and Hoyt's Clinical neuro-ophthalmology: the essentials. 6th ed. vol 3. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins; 2007. pp. 3755-3782.
18. Morell-Dubois S, Quemeneur T, Bourdon F, et al. Central retinal artery occlusion in Wegener's granulomatosis. Rev Med Interne 2007; 28:33-37.
19. Mueller AJ, Neubauer AS, Schaller U, et al. Evaluation of minimally invasive therapies and rationale for a prospective randomized trial to evaluate selective intra-arterial lysis for clinically complete central retinal artery occlusion. Arch Ophthalmol 2003; 128:1377-1381.
20. Landa E, Rehany U, Rumelt S. Visual functions following recovery from nonarteritic central retinal artery occlusion. Ophthalmic Surg Lasers Imaging 2004; 35:103-108.
21. Noble J, Weizblit N, Baerlocher MO, etal. Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review. Br J Ophthalmol 2008; 92:588- 593.
22. Justice J Jr, Lehmann RP. Cilioretinal arteries. A study based on review of stereo fundus photographs and fluorescein angiographic findings. Arch Ophthalmol 1976; 94:1355-1358.
23. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol 2005; 140:376-391.
24. David NJ, Norton EW, Gass JD, et al. Fluorescein angiography in central retinal artery occlusion. Arch Ophthalmol 1967; 77:619-629.
25. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125:509-520.
26. Kramer M, Goldenberg-Cohen N, Shapira Y, et al. Role of transesophageal echocardiography in the evaluation of patients with retinal artery occlusion. Ophthalmology 2001; 108:1461 -1464.
27. Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. Retinal survival time. Exp Eye Res 2004; 78:723-736.
28. Holschermann H, Krombach C, Jung A, etal. Treatment of acute central retinal artery occlusion with the platelet glycoprotein llb/llla receptor inhibitor tir- ofiban. Thromb Haemost 2005; 94:684-686.
29. Reynard M, Hanscom TA. Neodymium:yttrium-aluminum-garnet laser arter- iotomy with embolectomy for central retinal artery occlusion. Am J Ophthalmol 2004; 137:196-198.
30. Garcia-Arumi J, Martinez-Castillo V, Boixadera A, et al. Surgical embolus removal in retinal artery occlusion. Br J Ophthalmol 2006; 90:1252-1255.
31. Fraser S, Siriwardena D. Interventions for acute nonarteritic central retinal artery occlusion. Cochrane Database Syst Rev 2002:CD001989.
32. Hattenbach LO, Kuhli-Hattenbach C, Scharrer I, et al. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal
33. artery occlusion. Am J Ophthalmol 2008; 146:700-706. Intravenous thrombolytic therapy was administered to 17 eyes of patients with acute CRAO (<12 h). Overall, good visual outcome strongly correlated with time to treatment. Seven of 17 (41 %) eyes treated within 6.5 h had a visual acuity of 20/50 or better. In comparison, none of the 11 patients treated after 6.5 h from the onset of symptoms achieved a visual acuity of 20/50 or better. Of those patients who received i.v. thrombolytic therapy within 6.5 h, nine (53%) had three lines of improvement in vision. In comparison, no patient treated after 6.5 h had a similar improvement in vision.
34. Biousse V. Thrombolysis for acute central retinal artery occlusion: is it time? Am J Ophthalmol 2008; 146:631-634.
35. Biousse V, Calvetti O, Bruce BB, et al. Thrombolysis for central retinal artery occlusion. J Neuroophthalmol 2007; 27:215-230.
36. Lyden P. Thrombolytic therapy for acute stroke: not a moment to lose. N Engl J Med 2008; 359:1393-1395.
37. Kattah JC, Wang DZ, Reddy C. Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion. Arch Ophthalmol 2002; 120:1234-1236.
38. Hayreh SS. Intra-arterial thrombolysis for central retinal artery occlusion. Br J Ophthalmol 2008; 92:585-587.
39. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311 -322.
40. Suwanwela N, Koroshetz WJ. Acute ischemic stroke: overview of recent therapeutic developments. Annu Rev Med 2007; 58:89-106.
41. Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008; 39:3268-3276.
42. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
43. Mames RN, Shugar JK, Levy N, et al., CRAO Study Group. Peripheral thrombolytic therapy for central retinal artery occlusion. Arch Ophthalmol 1995; 113:1094.
44. Paques M, Vallee JN, Herbreteau D, et al. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Br J Ophthalmol 2000; 84:1387-1391.
45. Richard G, Lerche RC, Knospe V, et al. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology 1999; 106:768-773.
46. Wirostko WJ, Pulido JS, Hendrix LE. Selective thrombolysis of central retinal artery occlusion without long-term systemic heparinization. Surg Neurol 1998; 50:408-410.
47. Padolecchia R, Puglioli M, Ragone MC, et al. Superselective intraarterial fibrinolysis in central retinal artery occlusion. AJNR Am J Neuroradiol 1999; 20:565-567.
48. Framme C, Spiegel D, Roider J, et al. Central retinal artery occlusion. Importance of selective intra-arterial fibrinolysis. Ophthalmologe 2001; 98:725-730.
49. Rossmann H. The thrombolytic therapy of vascular occlusions of the retina [in German]. Klin Monatsbl Augenheilkd 1966; 149:874-880.
50. Lohse K, Weller P. Thrombolytic treatment of acute vascular occlusions in ophthalmology [in German]. Klin Monatsbl Augenheilkd 1969; 154:167- 174.
51. Coscas G, Samama M, Conard J, et al. Central retinal artery obliteration and streptokinase [in French]. Bull Soc Ophtalmol Fr 1969; 69:535- 538.
52. Sautter H, Rossmann H. Therapy of vascular occlusive disease of the retina with fibrinolysis [in German]. Angiologica 1971; 8:303-317.
53. Guadalupi U, Gattuccio S, Zilli R, et al. Medical treatment of central retinal artery occlusion with functional recovery [in Italian]. BollOcul 1981; 60:779- 788.
54. Annonier P, Benichou C, Flament J, et al. Role of fibrinolysis in the treatment of retinal arterial occlusion: discussion of 5 cases [in French]. Bull Soc Ophtalmol Fr 1988; 88:1167-1171.
55. Bertram B, Wolf S, Fisches H, et al. Thrombolytic treatment of retinal arterial occlusions with plasminogen activator [in German]. Klin Monatsbl Augen heilkd 1991; 198:295-300.
56. Barth H, Stein H, Fasse A, et al. Intracerebral hemorrhage after systemic thrombolysis in patients with occlusion of the central retinal artery: report of 2 cases [in German]. Ophthalmologe 1996; 93:739-744.
57. von Mach MA, Guz A, Wiechelt J, et al. Systemic fibrinolytic therapy using urokinase in central retinal artery occlusion: a case study [in German]. Dtsch Med Wochenschr 2005; 130:1002-1006.
58. Arnold M, Koerner U, Remonda L, et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatry 2005; 76:196-199.
59. Beatty S, Au Eong KG. Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data. Br J Ophthalmol 2000; 84:914-916.
60. Aldrich EM, Lee AW, Chen CS, er al. Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience. Stroke 2008; 39:1746- 1750.
61. This nonrandomized, single-center study evaluated the benefits of administering 3mg aliquots of intraarterial tPA in 42 patients compared with 21 patients who received conventional therapy. Seventy-six percent of patients who received intraarterial thrombolytic therapy had at least one line of visual acuity improvement compared with only 33% of patients who received conventional therapy. In addition, 33% of patients in the intraarterial thrombolytic therapy group experienced an improvement of three lines or more of vision compared with only 4.8% of patients in the conventional therapy group.
62. Schumacher M, Schmidt D, Wakhloo AK. Intraarterial fibrinolytic therapy in central retinal artery occlusion. Neuroradiology 1993; 35:600-605.
63. Biousse V, Trobe JD. Transient monocular visual loss. Am J Ophthalmol 2005; 140:717-721.
64. Goldstein LB. Acute ischemic stroke treatment in 2007. Circulation 2007; 116:1504-1514.
65. Pan CF, Shen MY, Wu CJ, et al. Inhibitory mechanisms of gabapentin, an antiseizure drug, on platelet aggregation. J Pharm Pharmacol 2007; 59:1255-1261.
66. Yamashita T, Oda E, Giddings JC, et al. The effect of dietary Bacillus natto productive protein on in vivo endogenous thrombolysis. Pathophysiol Hae- most Thromb 2003; 33:138-143.
67. Suzuki Y, Kondo K, Matsumoto Y, et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci 2003; 73:1289- 1298.
68. Opremcak E, Rehmar AJ, Ridenour CD, et al. Restoration of retinal blood flow via translumenal Nd:YAG embolysis/embolectomy (TYL/E) for central and branch retinal artery occlusion. Retina 2008; 28:226-235.
69. Feltgen N, Neubauer A, Jurklies B, et al. Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1 EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol 2006; 244:950-956.
70. Hayreh SS. Comment re: multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. Graefes Arch Clin Exp Ophthalmol 2007; 245:464-466; author reply 467-470.
71. Liang BA, Lew R, Zivin JA. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues. Arch Neurol 2008; 65:1429-1433.
72. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1045-1055.
73. Gorelick AR, Gorelick PB, Sloan EP. Emergency department evaluation and management of stroke: acute assessment, stroke teams and care pathways. Neurol Clin 2008; 26:923-942.